The U.S. has ceded its leadership in critical industries before. It must not do so with China and biotech now, writes the ...

The titles of more than 700 multi-year NIH grants have been changed this year, according to an analysis by Jeremy Berg, a ...

Seth Berkley, former CEO of Gavi, the Vaccine Alliance and co-founder of COVAX, discusses his new book “Fair Doses” and the ...

With chatbots, information-seeking is a conversation, which means it’s relational. That “relationship” might look like the ...

What do Rollerblades and Ozempic have in common? Host Alex Hogan explains in the latest episode of STATus Report.

Every clinician knows the drill: ask about substance use, sleep, diet, exercise, and housing. The social history is the part ...

A psychedelic-like therapy posted encouraging early data, as regulators cleared the drug — not a hallucinogenic — for at-home ...

Eli Lilly announced a partnership with chipmaker NVIDIA to build what it claims will be the “most powerful supercomputer ...

The company plans to revamp its enterprise of 90,000 clinicians into one more heavily weighted toward employed physicians, ...

The number of people using injectable obesity treatments is increasing rapidly, and it is leading to declines in obesity, ...

Bausch Health has exited Medicaid and a federal government drug discount scheme known as 340B, a step that suggests more ...

Texas Attorney General Ken Paxton on Tuesday accused the companies behind Tylenol of deceptively marketing the pain reliever ...